<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00791947</url>
  </required_header>
  <id_info>
    <org_study_id>NLG-T-01</org_study_id>
    <secondary_id>2006-000389-35</secondary_id>
    <nct_id>NCT00791947</nct_id>
  </id_info>
  <brief_title>A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT</brief_title>
  <official_title>A Nordic Phase II Study of Peripheral T-cell Lymphomas Based on Dose-intensive Induction and High-dose Consolidation With Autologous Stem Cell Rescue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Lymphoma Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II prospective non-randomised clinical trial in newly diagnosed and
      previously untreated adult patients in the age range 18-60 (67) years with peripheral T-cell
      lymphoma.

      The treatment schedule will consist of three phases: induction and high-dose consolidation,
      followed by autologous stem cell rescue. There will be two different induction schedules: one
      for patients in the age range 18-60 years and one for patients aged over 60 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">166</enrollment>
  <condition>Peripheral T-Cell Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOEP + G-CSF followed by BEAM</intervention_name>
    <description>CHOEP:
Cyclophosphamide: 750 mg/m2 i.v. day1 Hydroxydaunorubicin: 50 mg/m2 i.v. day1 Vincristine: 1.4 mg/m2 (max 2 mg) i.v. day 1 Etoposide: 100 mg/m2 i.v. day 1-3 Prednisone: 100 mg daily p.o. day 1-5
BEAM:
Carmustine: 300 mg/m2 i.v. day 1 Etoposide: 100 mg/m2 i.v. x2 daily day 2-5 Cytosine arabinoside: 200 mg/m2 i.v. x2 daily or 400 mg/m2 as continuous 24 hrs i.v. infusion, day 2-5 Melphalan: 140 mg/m2 i.v. day 6</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated patients with newly diagnosed peripheral T-cell lymphoma of all
             stages. However, patients with nodal stage IA non-bulky disease (&lt;10cm) can be treated
             individually at the discretion of the responsible physician.

          -  Following histologic subtypes (WHO classification) are eligible for inclusion in the
             study:

        Peripheral T-cell lymphomas, unspecified Angioimmunoblastic T-cell lymphoma NK/T nasal-type
        T-cell lymphoma Enteropathy-type T-cell lymphoma Primary systemic, alk-negative anaplastic
        large cell lymphoma (T-or null phenotype) Hepatosplenic T-cell lymphoma Subcutaneous
        panniculitis-like T-cell lymphoma

        NB: Patients should not enter the treatment program before confirmation of the
        histo-pathological diagnosis by the referral center pathologist

          -  Age 18-60 years. Patients in the age range 61-67 years may be included in this
             protocol at discretion of the treating physician.

          -  formed consent based on oral and written patient information (Appendix I)

        Exclusion Criteria:

          -  Primary cutaneous T-or null-cell anaplastic large-cell lymphoma

          -  Alk-positive, primary systemic T-or null-cell anaplastic large-cell lymphoma

          -  WHO Performance Status grade 4 (Appendix II)

          -  Patients with severe cardiac (i.e. severe heart failure requiring symptomatic
             treatment or a cardiac ejection fraction of less than 45%), pulmonary, neurologic,
             psychiatric, renal, hepatic or metabolic disease.

          -  Pregnancy. N.B: Women of childbearing potential should be strongly advised to apply
             appropriate contraceptive precautions during the entire treatment period.

          -  Patients with concomitant malignancies except for non-melanoma skin tumors or stage 0
             (in situ) cervical carcinoma.

          -  Patients with seropositivity for the human immunodeficiency virus.

          -  Patients with other active and therapeutically uncontrolled infection.

          -  Psychological, familial, social or other condition/-s potentially hampering compliance
             and follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>67 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco d'Amore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nordic Lymphoma Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copenhagen Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OULO University Hospital</name>
      <address>
        <city>Oulu</city>
        <state>Oulo</state>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ullevaal University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rogaland Hospital</name>
      <address>
        <city>Rogaland</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2008</study_first_submitted>
  <study_first_submitted_qc>November 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2008</study_first_posted>
  <last_update_submitted>September 7, 2011</last_update_submitted>
  <last_update_submitted_qc>September 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

